OK Biotech Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 13, 2022
Share
OK Biotech Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 308.37 million compared to TWD 309.09 million a year ago. Net income was TWD 46.34 million compared to TWD 15.29 million a year ago. Basic earnings per share from continuing operations was TWD 0.4446 compared to TWD 0.1452 a year ago. Diluted earnings per share from continuing operations was TWD 0.3902 compared to TWD 0.1361 a year ago. Basic earnings per share was TWD 0.4446 compared to TWD 0.1452 a year ago. Diluted earnings per share was TWD 0.3902 compared to TWD 0.1361 a year ago.
For the nine months, sales was TWD 1,161.39 million compared to TWD 905.55 million a year ago. Net income was TWD 148.82 million compared to TWD 44.89 million a year ago. Basic earnings per share from continuing operations was TWD 1.4245 compared to TWD 0.4355 a year ago. Diluted earnings per share from continuing operations was TWD 1.2158 compared to TWD 0.4083 a year ago. Basic earnings per share was TWD 1.4245 compared to TWD 0.4355 a year ago. Diluted earnings per share was TWD 1.2158 compared to TWD 0.4083 a year ago.
OK Biotech Corporation is principally engaged in the manufacture and distribution of medical supplies and products. The Company primarily provides household medical glucose meters and disposable glucose testing strips. Its products are applied in the testing and monitoring of glucose value for diabetes patients, hospitals, clinic doctors and nurses, among others. The Company distributes its products principally in Taiwan, other Asian markets and the United States.
OK BIOTECH CO., LTD. 
